In our study, we identified that SMS2 upregulated the expression of FLOT 2 and enhanced the stemness of breast cancer cells through NF-κB signaling pathway, which eventually resulted in increased resistance to the chemotherapeutic drug adriamycin (ADR). The gene discussed is SGMS2; the disease is breast carcinoma.